VeriMomVeriMom
HIGH RISK

임신 중 minoxidil succinoyl oligopeptide-143을 피해야 할까요? | VeriMom

Minoxidil (6-(piperidinyl)-2,4-pyrimidinediamine-3-oxide) is listed as a substance that must not form part of the composition of cosmetics in EU Annexes (minoxidil and its salts appear in the prohibited list), which by your rules requires h≥2. Topical minoxidil is systemically absorbed in measurable amounts and there are case reports of effects in infants after dermal exposure; therefore a mechanism of systemic exposure is plausible. No SCCS/CIR opinion or harmonised H360/H361 specific to the peptide was found; evidence is via minoxidil data and regulatory prohibition. Sources: EU Annex listing, PubChem/minoxidil, EMA safety note on infant hypertrichosis.

What to use instead

Pregnancy-safe ingredients that serve a similar function:

FAQ

minoxidil succinoyl oligopeptide-143은 임신 중 안전한가요?
Minoxidil (6-(piperidinyl)-2,4-pyrimidinediamine-3-oxide) is listed as a substance that must not form part of the composition of cosmetics in EU Annexes (minoxidil and its salts appear in the prohibited list), which by your rules requires h≥2. Topical minoxidil is systemically absorbed in measurable amounts and there are case reports of effects in infants after dermal exposure; therefore a mechanism of systemic exposure is plausible. No SCCS/CIR opinion or harmonised H360/H361 specific to the peptide was found; evidence is via minoxidil data and regulatory prohibition. Sources: EU Annex listing, PubChem/minoxidil, EMA safety note on infant hypertrichosis.
minoxidil succinoyl oligopeptide-143은 모유 수유 중 안전한가요?
Minoxidil is a pharmacologically active systemic agent with reports of infant effects after maternal topical use and some evidence of transmission/infant exposure; regulatory guidance warns about infant hypertrichosis following skin contact. Thus breastfeeding safety is a concern (h=2). Mechanistic concern is demonstrated systemic exposure; measured transfer into milk is not well-quantified in public cosmetic dossiers, so exposure is graded as low but measurable for breastfeeding (e=1).
minoxidil succinoyl oligopeptide-143은 아기 피부에 안전한가요?
For dermal contact with infants (0–3 yr) there are case reports of excessive hair growth in infants after parental topical minoxidil use/contact, and infants have higher dermal uptake (immature barrier and higher surface-area-to-weight). Therefore hazard and mechanism scores follow minoxidil (h=2, m=2) and exposure is increased (adult e=2 → infant e=3 per your rules). No infant-specific toxicology studies for the peptide were found; the concern is driven by the minoxidil parent compound and case reports.
VeriMom은 minoxidil succinoyl oligopeptide-143을 어떻게 평가하나요?
VeriMom은 EU CosIng, ECHA 분류, PubMed 연구를 기반으로 minoxidil succinoyl oligopeptide-143을 33/100 (높은 위험)로 평가합니다.
임신 중 minoxidil succinoyl oligopeptide-143 대체 안전 성분은?
유사한 기능을 가진 알려진 위험이 없는 대체 성분 목록을 확인하세요.

모든 성분표를 2초 만에 확인

VeriMom 무료 다운로드 — 어떤 제품이든 스캔해 임신 중 안전 점수를 즉시 확인하세요.

의료 면책 조항

이 정보는 교육 목적으로만 제공되며 의학적 조언을 구성하지 않습니다. 안전 점수는 공개적으로 이용 가능한 데이터를 기반으로 하며 모든 위험을 반영하지 않을 수 있습니다. 임신 중 또는 수유 중 제품을 사용하기 전에 항상 의료 전문가와 상담하십시오.

VeriMom 앱에서 모든 기능을 이용해 보세요